Trial Profile
Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Iltamiocel (Primary)
- Indications Stress incontinence; Urinary incontinence
- Focus Adverse reactions
- Acronyms IND1
- Sponsors Cook MyoSite
- 16 May 2017 Results from NCT00847535, NCT01008943 and NCT01382602 studies, presented at the 112th Annual Meeting of the American Urological Association.
- 30 Jan 2015 New trial record